KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
April 22 2024 - 5:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of oral, small molecule protease inhibitors,
today announced that William C. Fairey has been appointed to the
Company’s Board of Directors, effective immediately. Mr. Fairey was
most recently the Chief Commercial Officer at MyoKardia, Inc., a
clinical stage biopharmaceutical company, and is a business leader
with significant experience building markets and launching novel
therapeutics to treat specialty and rare/orphan diseases.
“We welcome Bill to our Board of Directors,” said Ben Palleiko,
CEO of KalVista. “His experience in commercial and medical
strategy, operations and product launches within the rare disease
space will be invaluable to us as we continue our evolution into a
commercial organization and focus on the FDA submission, potential
approval and commercial launch of sebetralstat.”
“I’m excited to join KalVista’s board on the cusp of such a
significant milestone as the planned FDA filing, and I look forward
to helping advance the commercialization of sebetralstat,” said Mr.
Fairey. “I believe KalVista has the opportunity to change the
treatment paradigm in the hereditary angioedema space by delivering
an efficacious and well-tolerated, oral on-demand treatment to the
people living with this debilitating disease.”
Mr. Fairey has more than 30 years of experience in commercial
and medical operations in the biotechnology and pharmaceutical
industry, including shaping markets, developing products,
determining global commercial/medical strategies, and leading
cross-functional teams in delivering successful new product
launches. Prior to MyoKardia, he served as Chief Operating Officer
at ChemoCentryx, Inc. and held several positions of increasing
responsibility at Actelion Pharmaceuticals, including serving as
President for its US division, Vice President of the Asia Pacific
Region, and President of Actelion Canada. He has also held several
senior business, sales and market access roles at the Parke-Davis
division of Warner-Lambert and has previously served on several
life science company boards. Mr. Fairey received his M.B.A. from
St. Mary’s College of California and his B.S. from the University
of Oregon.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista disclosed positive phase 3 data
for the KONFIDENT trial for its oral, on-demand therapy
sebetralstat in February 2024. The Company anticipates submitting a
new drug application to the U.S. FDA for sebetralstat in the first
half of 2024 and expects to file for approval in Europe and Japan
later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor
program represents a new generation of therapies that may further
improve the treatment for people living with HAE and other
diseases.
For more information about KalVista, please visit
www.kalvista.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and their results, our ability to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2023, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422400971/en/
KalVista Pharmaceuticals, Inc. Jarrod Aldom Vice
President, Corporate Communications (201) 705-0254
jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2024 to May 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From May 2023 to May 2024